Tag: 200-300

On November 2, 2016, Tian, Maoqun; Yan, Ming; Baran, Phil S. published an article.SDS of cas: 152213-63-3 The title of the article was 11-Step Total Synthesis of Araiosamines. And the article contained the following:

A concise route to a small family of exotic marine alkaloids known as the araiosamines has been developed, and their absolute configuration has been assigned. The dense array of functionality, high polarity, and rich stereochem. coupled with equilibrating topologies present an unusual challenge for chem. synthesis and an opportunity for innovation. Key steps involve the use of a new reagent for guanidine installation, a remarkably selective C-H functionalization, and a surprisingly simple final step that intersects a presumed biosynthetic intermediate. Synthetic araiosamines were shown to exhibit potency against Gram-pos. and -neg. bacteria despite a contrary report of no activity. The experimental process involved the reaction of Methyl 2-(6-bromo-1H-indol-3-yl)acetate(cas: 152213-63-3).SDS of cas: 152213-63-3

The Article related to araiosamine biomimetic preparation antibacterial gram pos neg, guanidinylation agent araiosamine preparation, carbon hydrogen bond functionalization araiosamine preparation and other aspects.SDS of cas: 152213-63-3

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles

On June 4, 2009, Deng, Jianghe; Kerns, Jeffrey K.; Jin, Qi; Lin, Guoliang; Lin, Xichen; Lindenmuth, Michael; Neipp, Christopher; Nie, Hong; Thomas, Sonia M.; Widdowson, Katherine L. published a patent.Safety of Methyl 5-bromoindoline-7-carboxylate The title of the patent was Preparation of novel indolecarboxamides as IKK2 inhibitors. And the patent contained the following:

The title compounds I [R1 = XYZ, tetrahydroisoquinolinyl, dihydroisoindolyl; X = (un)substituted Ph, heteroaryl, etc.; Y = a bond or alkylene; Z = NR4R5 or heterocycloalkyl; R2, R3 = H, F, Cl; R4 = H, alkyl (optionally substituted with one hydroxy or one methoxy group); R5 = H, heterocycloalkyl, alkoxy, etc.; U = a bond, alkylene or alkenylene; V = Ph, 5-6 membered heteroaryl, 5-7 membered heterocycloalkyl, etc.] which are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease), were prepared E.g., a multi-step synthesis of II, starting from indoline, was given. Selected compounds I were tested for activity against IKK2 (data given for representative compounds I). The invention is further directed to pharmaceutical compositions comprising a compound I. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound I or a pharmaceutical composition comprising a compound I. The experimental process involved the reaction of Methyl 5-bromoindoline-7-carboxylate(cas: 860624-88-0).Safety of Methyl 5-bromoindoline-7-carboxylate

The Article related to indolecarboxamide preparation ikk2 inhibitor antirheumatic antiasthmatic copd treatment, indole amide preparation ikk2 inhibitor antirheumatic antiasthmatic copd treatment and other aspects.Safety of Methyl 5-bromoindoline-7-carboxylate

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles

On January 11, 2007, Deng, Jianghe; Kerns, Jeffrey K.; Jin, Qi; Lin, Guoliang; Lin, Xichen; Lindenmuth, Michael; Neipp, Christopher E.; Nie, Hong; Thomas, Sonia M.; Widdowson, Katherine L. published a patent.Computed Properties of 860624-88-0 The title of the patent was Preparation of novel indolecarboxamides as IKK2 inhibitors. And the patent contained the following:

The title compounds I [R1 = XYZ, tetrahydroisoquinolinyl, dihydroisoindolyl; X = (un)substituted Ph, heteroaryl, etc.; Y = a bond or alkylene; Z = NR4R5 or heteroocycloalkyl; R2, R3 = H, F, Cl; R4 = H, alkyl (optionally substituted with one hydroxy or one methoxy group); R5 = H, heterocycloalkyl, alkoxy, etc.; U = a bond, alkylene or alkenylene; V = Ph, 5-6 membered heteroaryl, 5-7 membered heterocycloalkyl, etc.] which are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease), were prepared E.g., a multi-step synthesis of II, starting from indoline, was given. Selected compounds I were tested for activity against IKK2 (data given for representative compounds I). The invention is further directed to pharmaceutical compositions comprising a compound I. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound I or a pharmaceutical composition comprising a compound I. The experimental process involved the reaction of Methyl 5-bromoindoline-7-carboxylate(cas: 860624-88-0).Computed Properties of 860624-88-0

The Article related to indolecarboxamide preparation ikk2 inhibitor antirheumatic antiasthmatic copd treatment, indole amide preparation ikk2 inhibitor antirheumatic antiasthmatic copd treatment and other aspects.Computed Properties of 860624-88-0

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles

On March 30, 2006, Kerns, Jeffrey K.; Lindenmuth, Michael; Lin, Xichen; Nie, Hong; Thomas, Sonia M. published a patent.Electric Literature of 860624-88-0 The title of the patent was Indole derivatives as IKK2 inhibitors and their preparations, pharmaceutical compositions, and use for treatment of diseases associated with inappropriate IKK2 activity such as rheumatoid arthritis, asthma and chronic obstructive pulmonary disease. And the patent contained the following:

The invention is directed to indole carboxamide derivatives of formula I. Compounds of formula I wherein R1 is H, halo or YZ; R2 and R3 are independently H, F or Cl; Y is a bond, C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene; Z is (un)substituted (hetero)aryl; U is a bond, C1-6 alkylene or C2-6 alkenylene; V is (un)substituted Ph, (un)substituted 5- or 6-membered heteroaryl, (un)substituted 5- to 7-membered heterocycloalkyl, (un)substituted C5-7 cycloalkyl or (un)substituted C5-7 cycloalkenyl; and their pharmaceutically acceptable salts, solvates, or polymorphs thereof are claimed in this invention. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKss) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. Example compound II was prepared by N-Boc protection of indoline followed by acylation with Me chloroformate to give Me 1-(tert-butoxycarbonyl)indoline-7-carboxylate, which underwent bromination to give 5-bromo derivative, which was deprotected; the resulting Me 5-bromoindoline-7-carboxylate was dehydrated to give the Me 5-bromoindolecarboxylate, which upon hydrolysis gave the 5-bromo-7-indolecarboxylic acid, which underwent cross-coupling with phenylboronic acid; the resulting 5-phenylindole-7-carboxylic acid was converted to the corresponding indolecarboxamide, which underwent condensation with N-benzyl-4-piperidinone to give 3-(4-benzyl-1,2,3,6-tetrahydropyridin-4-yl)-5-phenylindole-7-carboxamide, which was subjected to hydrogenation; the resulting 3-(4-piperidinyl)-5-phenylindole-7-carboxamide was sulfonylated with 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethanesulfonyl chloride to give 3-[1-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethanesulfonyl]piperidin-4-yl]-5-methyl-1H-indole-7-carboxamide, which was reacted with to give compound II. Addnl. 315 example compounds were prepared by similar methods. All the invention compounds were evaluated for their IKK2 kinase inhibitory activity. From the IKK2 assay, it was determined that example compound II along with several other compounds have pIC50 values of 5.0 or greater. In the monocyte assay, most of the tested compound showed IC50 values or less than 10μM. The experimental process involved the reaction of Methyl 5-bromoindoline-7-carboxylate(cas: 860624-88-0).Electric Literature of 860624-88-0

The Article related to indole preparation pharmaceutical composition ikk2 inhibitor, ikk2 inhibitor treatment rheumatoid arthritis asthma copd indole preparation, treatment disease associated ikk2 indole preparation and other aspects.Electric Literature of 860624-88-0

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles

On November 29, 2012, Prime, Michael; Courtney, Stephen Martin; Marston, Richard; Dominguez, Celia; MacDonald, Douglas; Wityak, John published a patent.Application In Synthesis of 1-(Cyclopropanecarbonyl)indoline-5-sulfonyl chloride The title of the patent was Preparation of piperidin-4-yl substituted acrylamides as transglutaminase TG2 inhibitors. And the patent contained the following:

The title compounds I [A = (un)substituted (hetero)aryl, heterocycloalkyl; B = (un)substituted mono- or bicyclic heterocycloalkyl; R1 = H, NO2, COR (wherein R = H, alkyl, cycloalkyl, etc.), etc.; R2 = H or alkyl; R3-R5 = H, F, Cl, alkyl; p = 0-3; q = 0-1], were prepared E.g., a multi-step synthesis of the acrylamide II, starting from tert-Bu piperidin-4-ylcarbamate and 6-chloropyridine-3-sulfonyl chloride, was described. Exemplified compounds I were tested for human TG2 activity. Certain compounds I were found to have IC50 value less than 100 nM (no specific data given). Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington’s disease. Also described are methods of treatment which include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents. The experimental process involved the reaction of 1-(Cyclopropanecarbonyl)indoline-5-sulfonyl chloride(cas: 879562-21-7).Application In Synthesis of 1-(Cyclopropanecarbonyl)indoline-5-sulfonyl chloride

The Article related to piperidinyl acrylamide preparation transglutaminase tg2 inhibitor combination chemotherapy, neurodegenerative disorder huntington’s disease treatment piperidinyl acrylamide preparation and other aspects.Application In Synthesis of 1-(Cyclopropanecarbonyl)indoline-5-sulfonyl chloride

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles

On September 29, 2011, Tajima, Nobumitsu; Yamashita, Atsuyuki; Kondo, Yurie; Chikamatsu, Kaori; Hiramatsu, Naoki; Makino, Mitsuhiro; Kitamoto, Katsunori; Kataoka, Daisuke; Nagai, Kazushige; Goto, Izumi; Torii, Masashi; Suzuki, Kimie; Iwai, Hisakazu; Hirooka, Hiroko published a patent.Safety of Methyl 2-(6-bromo-1H-indol-3-yl)acetate The title of the patent was Preparation of novel indole derivatives ad glucokinase activators. And the patent contained the following:

The providing of compound which has a glucokinase activating action. N-heterocyclyl-2-indolylproppanamide derivatives [I; a solid line with a —- line = a single bond or a double bond; X-C-Y with a —- line = N-C:C or C:C-N; R1 = H, C1-6 alkyl, C2-6 alkenyl, C1-6 alkylsulfonyl, C1-6 alkyl-arylsulfonyl, arylsulfonyl, alkanoyl, aroyl, C1-6 alkylsulfonyl-aralkyl, aralkyl, alkanoylaryl, aryl, carboxyl-C1-6 alkyl, halo-C1-6 alkyl, hydroxy-C1-6 alkyl, amino-C1-6 alkyl, carbamoyl-C1-6 alkyl, etc.; R2 = H, C1-6 alkyl; R3 = C1-6 alkyl, C3-7 cycloalkyl, heteroaryl; R4 = H, halo, NO2; R5 = H, C1-6 alkyl, halo, aryl, C1-6 alkoxy, aralkyloxy, aroyl, alkanoyl; R6 = H, halo, alkanoyl-aryl, aryl, HO, aralkyloxy, C1-6 alkoxy, alkanoyl-C1-6 alkoxy, aroyl-C1-6 alkoxy, alkanoylaryloxy, aryloxy, NO2, alkanoyl, (un)substituted aroyl, CO2H, C1-6 alkoxycarbonyl, heteroaryl, aryl-C1-6 alkyl, aryl-hydroxy-C1-6 alkyl, etc.; R7 = H, C1-6 alkyl, halo, alkanoyl; R1 and R7 together with X-C-C to which they are attached form cyclohexanone ring; A ring = 5- or 6-membered monocyclic N-containing heterocyclyl optionally containing addnl. N or S which optionally fused to aryl or C5-7 cycloalkyl to form bicyclic heterocyclic ring, in particular thiazolyl, pyridyl, or benzothiazolyl; R8 = H, halo, NO2, cyano, C1-6 alkoxycarbonyl, aralkyloxycarbonyl, HO, CO2H, (un)substituted CONH2, carboxy-C1-6 alkyl, etc. ] or prodrugs thereof or pharmaceutically acceptable salts thereof. These compounds have glucokinase activating activity and are useful for the prevention or treatment of diabetes or diabetes complications such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, ischemic heart diseases, or arteriosclerosis. Thus, 9.4 mg 2-(6-acetyl-5-fluoro-1-methyl-1H-indol-3-yl)-3-cyclopentylpropionic acid was dissolved in 1.5 mL DMF , treated with 86.3 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 48.6 mg 1-hydroxy-1H-benzotriazole monohydrate, stirred at room temperature for 2 h, treated with 178 mg 1-[2-(2-Aminothiazol-4-yl)acetyl]piperidine-4-carboxylic acid Et ester, stirred at 70° for 20 h to give, after workup and thin layer silica gel chromatog., 93% 1-[2-[2-[[2-(6-acetyl-5-fluoro-1-methyl-1H-indol-3-yl)-3-cyclopentylpropionyl]amino]thiazol-4-yl]acetyl]piperidine-4-carboxylic acid Et ester (II). II and compound (III) activated human glucokinase by 539 and 1,048 fold, resp., in in vitro phosphorylation of D-glucose with ATP. The experimental process involved the reaction of Methyl 2-(6-bromo-1H-indol-3-yl)acetate(cas: 152213-63-3).Safety of Methyl 2-(6-bromo-1H-indol-3-yl)acetate

The Article related to indole preparation prevention treatment diabetes, diabetes complication prevention treatment indole preparation, heterocyclylindolylproppanamide preparation glucokinase activator, pyridylindolylcyclopentylpropanamide preparation glucokinase activator and other aspects.Safety of Methyl 2-(6-bromo-1H-indol-3-yl)acetate

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles

On August 19, 2010, Takahashi, Fumie; Imada, Sunao; Shiwaku, Masahiko; Kato, Koji; Fukahori, Hidehiko published a patent.Recommanded Product: 1-(Cyclopropanecarbonyl)indoline-5-sulfonyl chloride The title of the patent was Preparation of 2-(difluoromethyl)-1-(morpholinoheterocyclyl)benzimidazole derivatives as selective phosphatidyl inositol-3-kinase (PI3Kδ) inhibitors. And the patent contained the following:

The title compounds [I; R1 = A1, A2, A3 = CH or N, provided that at least 2 of A1-A3 are N; W = NH, O; R1 = Q, Q1; R2 = H, lower alkyl, hydroxy-lower alkyl; R3 = H, halo; B1, B2 = bond, C1-4 alkylene; B3 = O, S, NR0; B4 = (un)substituted CH, N; R0 = H, lower alkyl; R10 = H, (un)substituted lower alkenyl, lower alkynyl, optionally alkoxy-substituted phenyl-lower alkyl, phenyl-lower alkoxy-lower alkyl; R11 = H, R100, C(O)R101, C(O)O R102, (un)substituted CONH2, SO2R105; or NR10R11 = (un)substituted 3- to 8-membered monocyclic heterocyclyl containing 1-4 heteroatoms selected from O, S, and N; R100 = (un)substituted lower alkyl, lower alkynyl, each ring-(un)substituted cycloalkyl, cycloalkylalkyl, heterocyclyl, or heterocyclylalkyl, (un)substituted NH2; R101 = each (un)substituted lower alkyl, CONH2, or piperadinylcarbonyl, cyano, HO, lower alkoxy, etc.; R102 = lower alkyl; R105 = (un)substituted lower alkyl, lower alkenyl, etc.] or salts thereof were prepared It is found that these tri-substituted triazine derivative or tri-substituted pyrimidine derivatives have a selective inhibitory activity on PI3Kδ over PI3Kα and/or an inhibitory activity on the production of IL-2 and/or an inhibitory activity on the proliferation of B cells (including an inhibitory activity on the activation of B cells) and can be used as prophylactic or therapeutic agents for rejections in various types of organ transplantation, allergic diseases (e.g., asthma, atopic dermatitis), autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn diseases, systemic lupus erythematosus), hematol. tumors (e.g., leukemia) and others. Thus, a solution of 2.27 g 2-(difluoromethyl)-1-[2-(methylsulfonyl)-6-(morpholin-4-yl)pyrimidin-4-yl]-1H-benzimidazole in 57 mL N,N-dimethylacetamide was treated with 5.45 g trans-cyclohexane-1,4-diamine and 1.15 g K2CO3 and stirred at 100° for 1 h to give, after workup and silica gel chromatog., 2.21 g trans-N-[4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(morpholin-4-yl)pyrimidin-2-yl]cyclohexane-1,4-diamine (II). A mixture of 100 mg II, 0.04 mL pyridine, and 1 mL CH2Cl2 was treated with 0.04 mL 3-chloropropane-1-sulfonyl chloride under ice-cooling, stirred at room temperature overnight, and concentrated to give, after silica gel chromatog., the precursor. Th precursor was dissolved in 1 mL N,N-dimethylformamide, treated with 27 mg 60% NaH, stirred at 0° for 1 h and at room temperature for 2 h to give, after workup and silica gel chromatog., 6-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-N-[trans-4-(1,1-dioxoisothiazolidin-2-yl)cyclohexyl]-2-(morpholin-4-yl)pyrimidin-4-amine (III). III and urea derivative (IV) showed IC50 of 5.0 and 0.85 nM, resp., against human PI3Kδ and IC50 of 2,900 and 460 nM, resp., against human PI3Kα, resp. The experimental process involved the reaction of 1-(Cyclopropanecarbonyl)indoline-5-sulfonyl chloride(cas: 879562-21-7).Recommanded Product: 1-(Cyclopropanecarbonyl)indoline-5-sulfonyl chloride

The Article related to allergy, allergy inhibitors, antiasthmatics, antirheumatic agents, antitumor agents, asthma, atopic dermatitis, autoimmune disease, b cell, crohn disease, homo sapiens, human, interleukin 2 role: bsu (biological study, unclassified), biol (biological study) (production inhibitors), leukemia, neoplasm (hematol.), psoriasis, rheumatoid arthritis, systemic lupus erythematosus, transplant rejection (inhibitors), ulcerative colitis and other aspects.Recommanded Product: 1-(Cyclopropanecarbonyl)indoline-5-sulfonyl chloride

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles

Kelly, R. J.; Moser, B. C. published their research in HortScience on December 31 ,1983. The article was titled 《Influence of temperature and auxin on root regeneration by seedlings of Liriodendron tulipifera L》.Name: Potassium 4-(1H-indol-3-yl)butanoate The article contains the following contents:

Root regeneration and shoot growth of seedlings of L. tulipifera (tulip tree) increased as temperature of either the soil or aerial growing environment increased from 10° to 21°. IBA K salt  [60096-23-3] applied to the tap roots at 1000 mg/L, increased root regeneration and shoot growth when both air and soil temperatures were at 15.5° or 21°. When air temperature was maintained at 21° and soil temperature was varied from 10° to 21°, root regeneration and shoot growth increased as soil temperature increased. IBA increased root regeneration only when soil temperature was 21°. In the experiment, the researchers used Potassium 4-(1H-indol-3-yl)butanoate(cas: 60096-23-3Name: Potassium 4-(1H-indol-3-yl)butanoate)

Potassium 4-(1H-indol-3-yl)butanoate(cas: 60096-23-3) is auxin-family plant hormone, and is thought to be a precursor of indole-3-acetic acid (IAA) the most abundant and the basic auxin natively occurring and functioning in plants. IAA generates the majority of auxin effects in intact plants, and is the most potent native auxin.Name: Potassium 4-(1H-indol-3-yl)butanoate

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles

《Promotion of rooting in stem cuttings of several ornamental plants by pretreatment with acid or base》 was published in HortScience in 1977. These research results belong to Lee, C. I.; Paul, J. L.; Hackett, W. P.. SDS of cas: 60096-23-3 The article mentions the following:

Rooting of stem cuttings of Bougainvillea cv. San Diego Red, Ceratonia siliqua, Chrysanthemum morifolium cvs. Golden Anne and Mandalay, Euonymus japonica, cv. Yellow Edge, Euphorbia pulcherrima cv. Eckspoint C-1 Red, Hedera helix, Trachelospermum jasminoides, Juglans hindsii, Pistacia chinensis, and Salix laevigata was greatly promoted by basal dipping in 2N H2SO4 prior to applying 3000 ppm IBA K salt (I K salt) [60096-23-3]. Pretreatment with NaOH (pH 10.5) resulted in considerable increase of rooting of cuttings of Rhododendron cv. Sweetheart Supreme, Bougainvillea, Liquidambar styraciflua, Osmanthus heterophyllus cv. Ilicifolius, and Pinus radiataa. In the experiment, the researchers used Potassium 4-(1H-indol-3-yl)butanoate(cas: 60096-23-3SDS of cas: 60096-23-3)

Potassium 4-(1H-indol-3-yl)butanoate(cas: 60096-23-3) is auxin-family plant hormone, and is thought to be a precursor of indole-3-acetic acid (IAA) the most abundant and the basic auxin natively occurring and functioning in plants. IAA generates the majority of auxin effects in intact plants, and is the most potent native auxin.SDS of cas: 60096-23-3

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles

Category: indole-building-blockOn October 31, 2011 ,《Substrates, wounding, and growth regulator concentrations alter adventitious rooting of baldcypress cuttings》 appeared in HortScience. The author of the article were King, Andrew R.; Arnold, Michael A.; Welsh, Douglas F.; Watson, W. Todd. The article conveys some information:

In previous studies, baldcypress [Taxodium distichum (L.) Rich.] clones were selected for tolerance to high pH soils, drought and salt exposures, and ornamental characteristics. The objective of the current research was to determine the treatment combinations that yielded optimum root quantity (percentage) and rooted cutting quality (root number, length, dry mass, and shoot dry mass) on vegetative cuttings for a representative clone. Cuttings were treated with factorial combinations of one of four potassium salt of indole-3-butyric acid (K-IBA) concentrations 40, 5000, 10,000, 15,000 mg·L-1 (0, 20.72, 41.44, 62.16 mM, resp.), wounded or not wounded (1-cm long basal incision), and rooted in one of three substrates (100% perlite, 100% peatmoss, or 50% perlite:50% peatmoss). Data indicated a tradeoff between potential rooting quantity and root quality measurements in response to different substrates. Although rooting percentages were affected by substrates only at P ≤ 0.10 (53% in 100% perlite vs. 36% in 100% peatmoss), there were highly significant (P ≤ 0.0001) differences in rooted cutting potential among substrates as measured by the percentage of cuttings with basal callus. Cuttings placed in 100% perlite callused at 85%, whereas cuttings placed in 100% peatmoss callused at ≈53%. The 100% peatmoss treatment, however, yielded cuttings with significantly greater root quality for all measurements, except root number per cutting. Wounding cuttings proved to have deleterious effects on root quality measurements. Total root length was ≈14.5 cm for non-wounded cuttings and ≈10.8 cm for wounded cuttings. Increasing K-IBA concentrations did not significantly (P ≤ 0.05) affect rooting or callus percentages but did significantly affect root dry mass, total root length, and average root length per cutting. Total root length increased from 10.8 cm at 0 mg·L-1 K-IBA to 16 cm at 15,000 mg·L-1 K-IBA. Mean root number per cutting increased from ≈1.6 with wounded cuttings planted in 100% peatmoss to ≈3.1 with non-wounded cuttings planted in 100% perlite. Results suggested that high-quality softwood baldcypress cuttings should not be wounded, should be treated with 15,000 mg·L-1 K-IBA, and grown in a substrate with intermediate water-holding capacity to achieve an acceptable balance between rooting percentage and rooted cutting quality objectives. In the experiment, the researchers used many compounds, for example, Potassium 4-(1H-indol-3-yl)butanoate(cas: 60096-23-3Category: indole-building-block)

Potassium 4-(1H-indol-3-yl)butanoate(cas: 60096-23-3) is auxin-family plant hormone, and is thought to be a precursor of indole-3-acetic acid (IAA) the most abundant and the basic auxin natively occurring and functioning in plants. IAA generates the majority of auxin effects in intact plants, and is the most potent native auxin.Category: indole-building-block

Referemce:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles